Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1932 1
1950 1
1957 1
1991 2
1999 1
2000 1
2003 2
2004 1
2005 2
2006 3
2007 2
2008 5
2009 1
2011 3
2012 3
2013 4
2014 4
2015 5
2016 3
2017 4
2018 5
2020 1
2021 5
2022 4
2023 4
2024 5
2025 8
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean eich ml[au] (56 results)?
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD; endTB Clinical Trial Team. Guglielmetti L, et al. Among authors: rich ml. N Engl J Med. 2025 Jan 30;392(5):468-482. doi: 10.1056/NEJMoa2400327. N Engl J Med. 2025. PMID: 39879593 Free PMC article. Clinical Trial.
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis.
Seddon JA, Achar J, Malik AA, Hughes J, Burzynski J, Chen C, Denholm JT, Dravniece G, Fox GJ, Furin J, Geliukh E, Goncharova O, Guglielmetti L, Harries AD, Hesseling AC, Nguyen BH, Kavenga F, Khan U, Kherabi Y, Kiria N, Kock Y, Liu Q, Mesic A, Moore DAJ, Mubanga A, Naidoo L, Nilsen D, Piubello A, Reuter A, Rich ML, Satyanarayana S, Schaaf HS, Schoeman I, Skrahina A, Udwadia Z, Khan PY, Esmail H, Martinez L. Seddon JA, et al. Among authors: rich ml. Lancet Infect Dis. 2025 Dec;25(12):e692-e704. doi: 10.1016/S1473-3099(25)00157-4. Epub 2025 Jun 6. Lancet Infect Dis. 2025. PMID: 41036784 Review.
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Among authors: rich ml. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
Target regimen profiles for treatment of tuberculosis: a WHO document.
Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M. Lienhardt C, et al. Among authors: rich ml. Eur Respir J. 2017 Jan 25;49(1):1602352. doi: 10.1183/13993003.02352-2016. Print 2017 Jan. Eur Respir J. 2017. PMID: 28122858 Free PMC article. No abstract available.
Clinical best practices for caring for people with expanded resistance to newer TB drugs.
Nkomo T, Udwadia Z, Vambe D, van Rie A, Thi SS, Stillo J, Stambekova A, Sinha A, Rich ML, Reuter A, Patel J, Otto-Knapp R, Motta I, Mesic A, McKenna L, Maru S, Lessem E, Lange C, Kiria N, Kherabi Y, Günther G, Guglielmetti L, Decroo T, Chen L, Ashesh A, Abubakirov A, Furin J. Nkomo T, et al. Among authors: rich ml. IJTLD Open. 2025 Jun 13;2(6):315-323. doi: 10.5588/ijtldopen.25.0240. eCollection 2025 Jun. IJTLD Open. 2025. PMID: 40530383 Free PMC article. Review.
Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TB.
Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Law S, Kikvidze M, Kirakosyan O, Miankou A, Thit P, Mamsa S, Janmohamed A, Melikyan N, Ahmed S, Vargas D, Binegdie AB, Temirova K, Oyewusi L, Philippe K, Vilbrun SC, Khan U, Huerga H, Franke MF. Zeng C, et al. Among authors: rich ml. IJTLD Open. 2025 May 12;2(5):269-275. doi: 10.5588/ijtldopen.24.0515. eCollection 2025 May. IJTLD Open. 2025. PMID: 40365032 Free PMC article.
Shared learning in an interconnected world: innovations to advance global health equity.
Binagwaho A, Nutt CT, Mutabazi V, Karema C, Nsanzimana S, Gasana M, Drobac PC, Rich ML, Uwaliraye P, Nyemazi JP, Murphy MR, Wagner CM, Makaka A, Ruton H, Mody GN, Zurovcik DR, Niconchuk JA, Mugeni C, Ngabo F, Ngirabega Jde D, Asiimwe A, Farmer PE. Binagwaho A, et al. Among authors: rich ml. Global Health. 2013 Aug 30;9:37. doi: 10.1186/1744-8603-9-37. Global Health. 2013. PMID: 24119388 Free PMC article.
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
Rich ML, Khan U, Zeng C, LaHood A, Franke MF, Atwood S, Bastard M, Burhan E, Danielyan N, Dzhazibekova PM, Gadissa D, Ghafoor A, Hewison C, Islam MS, Kazmi E, Khan PY, Lecca L, Maama LB, Melikyan N, Naing YY, Philippe K, Saki NA, Seung KJ, Skrahina A, Tefera GB, Varaine F, Vilbrun SC, Võ L, Mitnick CD, Huerga H. Rich ML, et al. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):451-457. doi: 10.5588/ijtld.22.0613. Int J Tuberc Lung Dis. 2023. PMID: 37231598 Free PMC article.
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
Zeng C, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Atwood S, Melikyan N, Morchiladze N, Khachatryan N, Khmyz M, Restrepo CG, Salahuddin N, Kazmi E, Dahri AA, Ahmed S, Varaine F, Vilbrun SC, Oyewusi L, Gelin A, Tintaya K, Yeraliyeva LT, Hamid S, Khan U, Huerga H, Franke MF. Zeng C, et al. Among authors: rich ml. Int J Tuberc Lung Dis. 2023 Jan 1;27(1):34-40. doi: 10.5588/ijtld.22.0324. Int J Tuberc Lung Dis. 2023. PMID: 36853128 Free PMC article.
84 results